Vivos Inc. Issues Shareholder Update Letter

Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) – The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical studies at Mayo Clinic. Over the past several years, Vivos has successfully responded to inquiries from more than 40 unique FDA reviewers. Many items that we addressed were generated due to reviewer transitions. We are providing data and finalizing the approvable technical parameters with the FDA related to demonstrating the precision delivery of Radiogel to the treatment area and the minimal non-systemic migration of the radiopharmaceutical agent.